Are Pharma Partnerships the Wrong Strategy for DTx Companies?

While the digital therapeutics (DTx) market is increasingly growing, it is still small compared to large players in the healthcare industry such as pharma. Pharma’s money and resources, and their expertise in evidence generation, regulatory pathways and sales channels, have attracted many DTx companies. As a result, we have seen a lot of DTx - Pharma partnerships over recent years. However, we struggle to find clear success stories as DTx and pharma are still figuring out the right model. This often raises the question, is pharma the wrong strategy for DTx companies? Join us in a peer-to-peer discussion to deep dive into the following: